Kalorama

Science & Medicine Group Announces Top Life Science Editors to Lead LabPulse and The Science Advisory Board

Retrieved on: 
Tuesday, October 18, 2022

ARLINGTON, Va., Oct. 18, 2022 /PRNewswire/ -- Science and Medicine Group Inc. (SMG), a data intelligence company providing actionable insights about hard-to-reach audiences in the life sciences and healthcare, today announced the appointments of Leo O'Connor as Editor in Chief of LabPulse, and Greg Slabodkin as Editor in Chief of The Science Advisory Board. With decades of industry experience, these editorial leaders will support the expansion of two popular SMG-owned data and intelligence resources known for providing insights about scientific advancements, collaborations and trends across key market segments, including life science research, clinical laboratories, pharma, and biotech.

Key Points: 
  • The Science Advisory Board is an international community of life science and medicine experts immersed in biological research, drug discovery and biopharmaceutical production.
  • The Science Advisory Board is also a channel for researchers, professionals, trainees and advocates to stay on top of life science and biopharmaceutical news and trends.
  • "The Science Advisory Board community is one of the most intellectually stimulating, diverse and impressive groups of experts shaping the future of life science and drug discovery and development," said Slabodkin.
  • For more information about LabPulse, go to: www.labpulse.com
    For more information about Science Advisory Board, go to: www.scienceboard.net
    Science and Medicine Group is on a mission as a premier data intelligence company to deliver actionable insights about hard-to-reach audiences in science and medicine.

Predicting the Next Emerging Disease Requiring In Vitro Diagnostics (IVDs)

Retrieved on: 
Wednesday, October 12, 2022

ARLINGTON, Va., Oct. 12, 2022 /PRNewswire-PRWeb/ -- Kalorama estimates a $3.7 billion market for emerging diseases. This market is expected to grow to $4.9 billion in 2026. This is based on its recent report "Emerging Infectious Disease Market Trends, 2022."

Key Points: 
  • ARLINGTON, Va., Oct.12, 2022 /PRNewswire-PRWeb/ -- Kalorama estimates a $3.7 billion market for emerging diseases.
  • This is based on its recent report " Emerging Infectious Disease Market Trends, 2022 ."
  • For many mosquito-borne illnesses, there is no vaccine and little in the way of treatment as the infections are viral.
  • Non mosquito-spread diseases of concern include: Tuberculosis, Chagas, Lyme Disease Marburg virus, Rift Valley Fever, Ebola, Ross River Virus, CCHF, Nipah and Lassa Fever.

Global Vaccine Market Exceeds $200 Billion: Kalorama Information Report

Retrieved on: 
Thursday, October 6, 2022

ARLINGTON, Va., Oct. 6, 2022 /PRNewswire-PRWeb/ -- In 2022, the global market for vaccines is estimated to reach $202.6 billion. COVID-19 vaccines represent roughly two thirds of these revenues, according to Kalorama Information's just-published market research report "The 2022 World Market for Vaccines".

Key Points: 
  • ARLINGTON, Va., Oct. 6, 2022 /PRNewswire-PRWeb/ -- In 2022, the global market for vaccines is estimated to reach $202.6 billion.
  • COVID-19 vaccines represent roughly two thirds of these revenues, according to Kalorama Information's just-published market research report " The 2022 World Market for Vaccines ".
  • Kalorama's report estimates total sales earned by vaccine manufacturers such as Astra Zeneca, Pfizer, Moderna and Glaxo and others, and projects revenues in various vaccine product segments to 2027.
  • Companies use the Kalorama reports to benchmark market share, and investors and investment firms use reports to assess companies.

Science & Medicine Group Expands as Commercial Data Insights Leader with Amplion Acquisition

Retrieved on: 
Wednesday, September 7, 2022

The integration of the Amplion knowledgebase and next-generation data architecture will immediately expand SMG's capabilities to deliver more comprehensive, actionable insights to commercial organizations at life science equipment and reagent manufacturers as well as pharmaceutical services providers.

Key Points: 
  • The integration of the Amplion knowledgebase and next-generation data architecture will immediately expand SMG's capabilities to deliver more comprehensive, actionable insights to commercial organizations at life science equipment and reagent manufacturers as well as pharmaceutical services providers.
  • "With the Amplion acquisition, Science and Medicine Group is taking decisive action to build the premier data intelligence company serving commercial operations in the life science and healthcare industries.
  • This is the fourth strategic acquisition we have made, and we continue to look for opportunities that expand our unique positioning in the market and accelerate our growth," said Sam Osman, CEO, Science and Medicine Group.
  • Science and Medicine Group is on a mission as a premier data intelligence company to deliver actionable insights about hard-to-reach audiences in science and medicine.

COVID-19 Will Be With Us For Years, So Will a Large In Vitro Diagnostics Market

Retrieved on: 
Wednesday, August 31, 2022

 ARLINGTON, Va., Aug. 31, 2022 /PRNewswire/ -- The worldwide in vitro diagnostic (IVD) market will reach $127.4 billion dollars in 2022, according to IVD market research firm Kalorama Information.  That's the finding from the firm's 15th large-scale IVD industry report, The Worldwide Market for In Vitro Diagnostic Tests, released this month. The market will grow to $140.1 billion in 2027, and COVID-19 testing will drive that market. The larger part of the IVD market is non-COVID testing and diabetes and cancer testing products, which will also drive the industry to growth.  

Key Points: 
  • That's the finding from the firm's 15th large-scale IVD industry report, The Worldwide Market for In Vitro Diagnostic Tests , released this month.
  • The market will grow to $140.1 billion in 2027, and COVID-19 testing will drive that market.
  • Kalorama has called the IVD market for two decades in detailed reports based on company financial information, interviews and medical statistics (FOR MORE INFORMATION: https://kaloramainformation.com/product/the-worldwide-market-for-in-vitr... ).
  • But the bulk of the market sales in 2022, an estimated $94.8 billion, will be from non-COVID-19 IVD tests.

Q4 2021 IVD Market Brief Update - Featuring Abbott Laboratories, Danaher and Illumina Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022

The "IVD Market Brief Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "IVD Market Brief Update" report has been added to ResearchAndMarkets.com's offering.
  • This report is an update of the market for in vitro diagnostics products from Kalorama's analysts to reflect the latest information as of Q4 2021.
  • As part of its coverage, this report contains market sizing for several major categories of IVD.
  • The demand for testing and movement of current and new technologies has continued to demonstrate gains in most areas of the IVD market.

Point of Care Test Market is Ravaged, and Helped By Pandemic

Retrieved on: 
Tuesday, April 20, 2021

New COVID-19 tests fueled growth while the pandemic ravaged business in other test categories.

Key Points: 
  • New COVID-19 tests fueled growth while the pandemic ravaged business in other test categories.
  • This according to Kalorama\'s Information Worldwide Market for Point of Care .\n"Everywhere but infectious disease, this is a story of a declining market," said Bruce Carlson, Publisher of Kalorama Information, a Science and Medicine Group brand.
  • The market contracted in high single digits for 2019-2020.\nThe POC coagulation testing market was negatively affected by COVID-19.
  • The market contracted about more than 20%.\nMeanwhile, Kalorama said, the POC infectious disease market grew at over 300%, which made up for the entire market loss in other areas.

Digital Pathology Prospers Amid COVID-19 Challenge: Kalorama Report

Retrieved on: 
Monday, August 3, 2020

ARLINGTON, Va., Aug. 3, 2020 /PRNewswire-PRWeb/ -- A new report from market research firm Kalorama Information finds that digital pathology market is 710 million in 2020 and will grow 11.5% each year in the foreseeable future, driven by increasing acceptance of digital systems.

Key Points: 
  • ARLINGTON, Va., Aug. 3, 2020 /PRNewswire-PRWeb/ -- A new report from market research firm Kalorama Information finds that digital pathology market is 710 million in 2020 and will grow 11.5% each year in the foreseeable future, driven by increasing acceptance of digital systems.
  • Kalorama Information's recent study Digital Pathology Markets, 2020-2025, finds a vibrant market that is pushed by the need for faster cancer detection and the enhancements that IT systems, including artificial intelligence solutions provide.
  • Ten years ago, Roche reinforced its digital pathology business with the acquisition of a competitor that was integrated into Roche's Ventana Medical business.
  • Applied Spectral Imaging markets PathFusion, a digital pathology solution that combines whole slide imaging, digital FISH analysis and unique digital tissue matching of FISH with H&E/IHC samples.

Clinical Laboratory Business Showing Signs of Improvement, Says New Survey by Kalorama Information

Retrieved on: 
Thursday, June 25, 2020

Kalorama has been surveying labs across the U.S. about the number of tests they were running other than those to detect COVD-19.

Key Points: 
  • Kalorama has been surveying labs across the U.S. about the number of tests they were running other than those to detect COVD-19.
  • When the firm asked later in the month, 62% of labs were still reporting a major decline.
  • While still not optimal for the laboratory industry and IVD firms that sell products to them, the steep drop in clinical labs reporting major declines is promising, Kalorama says.
  • Kalorama also said that 15% of labs were now reporting "no decline" at all in non-COVID-19 test volumes; that number was 3% in May.

Molecular Diagnostics is Up, Other Test Volume is Down, Kalorama Survey Finds

Retrieved on: 
Tuesday, May 12, 2020

The results are part of the Kalorama Clinical Lab Tracker, a survey that was conducted in the third week of April by Science and Medicine Group company Kalorama Information, a market research firm that specializes in IVD.

Key Points: 
  • The results are part of the Kalorama Clinical Lab Tracker, a survey that was conducted in the third week of April by Science and Medicine Group company Kalorama Information, a market research firm that specializes in IVD.
  • Overall, 59% reported a significant impact from the COVID-19 pandemic, and the impact was stronger for those based in larger institutions.
  • Almost two-thirds of laboratories are concerned about that," Bruce Carlson, publisher of Kalorama Information, said during the webinar about the results.
  • Not surprisingly, the survey found that labs reported molecular assays volume was up (+7.7% on average) and tests like PCT, critical care and hospital infections were either up or not down significantly.